

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Ascher SHMULEWITZ) Group Art Unit: Not Yet Assigned
)
Application No.: Not Yet Assigned) Examiner: Not Yet Assigned
)
Filed: September 2, 2003)
)
For: PROSTHESIS COATING)
DECISION SUPPORT SYSTEM)

Mail Stop: Patent Application

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed with the patent application for the matter referenced above. Copies of the listed documents, including any copending patent applications, are attached. Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and applicants determine

that the cited documents do not constitute "prior art" under United States law,
Applicants reserve the right to present to the office the relevant facts and law regarding
the appropriate status of such documents.


Applicants further reserve the right to take appropriate action to establish the
patentability of the disclosed invention over the listed documents, should one or more of
the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please
charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: September 2, 2003

By: 
Karna J. Nisewaner
Reg. No. 50,665

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08875.0007-00000	Appln. No.	Not Yet Assigned
Applicant	Ascher SCHMULEWITZ		
Filing Date	September 2, 2003	Group:	Not Yet Assigned

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,871,436	02/16/1999	Eury	600	3	
	5,891,507	04/06/1999	Jayaraman	427	2.25	
	5,922,393	07/13/1999	Jayaraman	427	2.3	
	6,129,658	10/10/2000	Delfino et al.	600	3	
	6,214,115 B1	04/10/2001	Taylor et al.	118	423	
	6,245,104 B1	06/12/2001	Alt	623	1.46	
	6,246,992 B1	06/12/2001	Brown	705	2	
	6,309,380 B1	10/30/2001	Larson et al.	604	502	
	6,381,577 B1	04/30/2002	Brown	705	2	
	6,395,326 B1	05/28/2002	Castro et al.	427	2.24	
	6,450,956 B1	09/17/2002	Rappaport et al.	600	300	
	6,597,454 B1	07/22/2003	Berg et al.	356	418	
	6,171,232 B1	01/09/2001	Papandreou et al.	600	36	
	6,203,551 B1	03/20/2001	Wu	606	108	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Adler, L.M. et al, "Analysis of Exposure Times and Dose Escalation of Paclitaxel In Ovarian Cancer Cell Lines," Cancer, 74(7):1891-8, 1994.
	Carter, A.J., "Sirolimus: Pre-clinical Studies Evaluation of Dosing, Efficacy and Toxicity," presentation given at Transcatheter Cardiovascular Therapeutics, September 2001.
	Farb, A., "Comparative Pathology of Drug Eluting Stents: Insights Into Effectiveness and Toxicity from the Animal Lab," presentation given at the CRF Drug-Eluting Stent Symposium, March 2002.
	Hiatt, B.L. et al., "Drug-Eluting Stents for the Prevention of Restenosis: In Quest for the Holy Grail," Catheterization and Cardiovascular Interventions 55:409-417, 2002.
	Kalinowski, M et al., "Paclitaxel Inhibits Proliferation of Cell Lines Responsible for Metal Stent Obstruction: Possible Topical Application on Malignant Bile Duct Obstructions," Investigational Radiology 37(7):399-404, 2002.
	Kandzari, D.E. et al., "Highlights from American Heart Association Annual Scientific Sessions 2001: November 11 to 14, 2001," American Heart Journal 143(2), 217-228, 2002.
	Liebmann, J.E. et al., "Cytotoxic Studies of Paclitaxel (Taxol®) In Human Tumor Cell Lines," Br.J. Cancer, 68(6): 1104-9, 1993.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08875.0007-00000	Appln. No.	Not Yet Assigned
Applicant	Ascher SCHMULEWITZ		
Filing Date	September 2, 2003	Group:	Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Regar, E., "Stent Development and Local Drug Delivery," Br. Med. Bulletin, 59:227-48, 2001. See also http://www.tctmd.com/expert-presentations .

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce